• Теги
    • избранные теги
    • Компании1087
      • Показать ещё
      • Показать ещё
      Страны / Регионы265
      • Показать ещё
      Международные организации32
      • Показать ещё
      • Показать ещё
      • Показать ещё
      • Показать ещё
Novo Nordisk
26 июля, 17:11

Is a Beat in the Cards for Pfizer (PFE) in Q2 Earnings?

While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.

21 июля, 23:22

AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

21 июля, 15:52

Can Merck (MRK) Pull Off a Surprise this Earnings Season?

Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition.

21 июля, 15:50

Is Novo Nordisk (NVO) Stock a Solid Choice Right Now?

Novo Nordisk (NVO) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.

20 июля, 18:12

What Lies in Store for Glaxo (GSK) this Earnings Season?

The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.

19 июля, 16:17

Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

17 июля, 19:28

Why Did Radius Health (RDUS) Stock Plummet Today?

Shares of Radius Health (RDUS) dropped more than 7.8% in early morning trading hours Monday after the company announced that Jesper Hoiland, a former top-ranking executive at Novo Nordisk (NVO), has been appointed its new president and chief executive officer.

Выбор редакции
09 июля, 18:34

Shire gets injunction against Roche over hemophilia drug

Pharmaceutical group Shire (SHP.L) said on Sunday it had obtained a preliminary injunction in a Hamburg court against rival Roche (ROG.S) over its hemophilia drug emicizumab, alleging incomplete and misleading statements surrounding the treatment. Swiss drugmaker Roche is hoping to win a slice of the $11 billion-a-year hemophilia drug market with emicizumab, also known as ACE910 and designed to compete with more traditional treatments from Novo Nordisk (NOVOb.CO) and Shire.

26 июня, 16:30

The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk

The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk

26 июня, 12:59

New Roche haemophilia drug prevents bleeds but questions remain

Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year haemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire . Some analysts called Monday's data release convincing, with Jefferies saying it underpinned its $5 billion peak sales estimate for the medicine.

23 июня, 14:42

Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

22 июня, 17:57

Why You Should Add Novo Nordisk Stock to Your Portfolio

Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.

22 июня, 01:18

Top Analyst Reports for Caterpillar, Intel & Monsanto

Top Analyst Reports for Caterpillar, Intel & Monsanto

21 июня, 18:17

Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion

Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 17-2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk reduction in patients with type II diabetes.

16 июня, 21:26

Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why

Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.

14 июня, 22:34

Political Uncertainty in Finland: ETFs in Focus

The ruling coalition is at risk as Finns appointed anti-immigration Jussi Halla-aho as the leader of their party.

14 июня, 16:09

Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug

Novo Nordisk (NVO) announced positive results from the post-hoc analysis of the cardiovascular outcomes study, LEADER on Victoza.

12 июня, 15:43

Merck's Diabetes Drug Meets Primary Endpoint in Key Studies

Merck & Co., Inc. (MRK) and partner Pfizer Inc. (PFE) announced that its pipeline candidate, ertugliflozin, met primary endpoints in two late stage studies evaluating ertugliflozin in adults with Type 2 diabetes.

05 июня, 14:47

Key FDA Events to Watch Out for in Jun 2017

Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.

Выбор редакции